Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 14/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 12/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.48 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.37 |
| ▸ | CKS1B | P61024 | 1/20 | 0.33 |
| ▸ | SKP1 | P63208 | 1/20 | 0.33 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12262199 | 0.93 | OPRD1 (0.48) | OPRD1KCNH2CYP2D6MRGPRX2GPR119 | |
| SCHEMBL471472 | 0.90 | OPRD1 (0.52) | OPRD1KCNH2CYP2D6MRGPRX2GPR119 | |
| SCHEMBL16359483 | 0.90 | OPRD1 (0.50) | OPRD1KCNH2CYP2D6MRGPRX2 | |
| SCHEMBL16315367 | 0.88 | OPRD1 (0.48) | OPRD1KCNH2CYP2D6MRGPRX2 | |
| SCHEMBL10257763 | 0.87 | OPRD1 (0.55) | OPRD1KCNH2CYP2D6MRGPRX2GPR119 | |
| SCHEMBL12262138 | 0.86 | OPRD1 (0.65) | OPRD1KCNH2CYP2D6 | |
| SCHEMBL12262194 | 0.83 | OPRD1 (0.51) | OPRD1KCNH2CYP2D6MRGPRX2GPR119 | |
| SCHEMBL12262163 | 0.82 | OPRD1 (0.53) | OPRD1KCNH2CYP2D6GPR119 | |
| SCHEMBL471517 | 0.82 | OPRD1 (0.53) | OPRD1KCNH2CYP2D6GPR119 | |
| SCHEMBL471543 | 0.80 | GPR119 (0.43) | OPRD1KCNH2CYP2D6MRGPRX2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2399577-A1 | Use of N-containing spirocompounds for the enhancement of cognitive function | Adolor Corporation (US) | 2011-12-28 | — | — | EP | disclosed |
| US-8022060-B2 | Spirocyclic heterocyclic derivatives and methods of their use | ADOLOR CORPORATION (US) | 2011-09-20 | — | — | US | disclosed |
| US-8022060-B2 | Spirocyclic heterocyclic derivatives and methods of their use | ADOLOR CORPORATION (US) | 2011-09-20 | — | — | US | disclosed |
| US-20110218186-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2011-09-08 | — | — | US | disclosed |
| US-20110218186-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2011-09-08 | — | — | US | disclosed |
| US-20100029614-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100029614-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2010-02-04 | — | — | US | disclosed |
| US-7598261-B2 | Spirocyclic heterocyclic derivatives and methods of their use | ADOLOR CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598261-B2 | Spirocyclic heterocyclic derivatives and methods of their use | ADOLOR CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080119452-A1 | METHODS FOR ENHANCING COGNITIVE FUNCTION | CALIXA THERAPEUTICS, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080119452-A1 | METHODS FOR ENHANCING COGNITIVE FUNCTION | CALIXA THERAPEUTICS, INC. | 2008-05-22 | — | — | US | disclosed |
| WO-2008033299-A2 | USE OF N-CONTAINING SPIROCOMPOUNDS FOR THE ENHANCEMENT OF COGNITIVE FUNCTION | ADOLOR CORPORATION (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218186-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | OPRK1, OPRD1, OPRL1 | OPRD1 2/4885KCNH2 1285/4885CYP2D6 138/4885 |
| US-20080119452-A1 | METHODS FOR ENHANCING COGNITIVE FUNCTION | CHAT, GRIN2C, GRIN2A | OPRD1 981/4885KCNH2 1960/4885CYP2D6 1113/4885 |
| US-20100029614-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | OPRK1, OPRD1, OPRL1 | OPRD1 2/4885KCNH2 1285/4885CYP2D6 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.